NL-OMON37832撤回不适用
The impact of 18 weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC) on skeletal muscle composition of female breast cancer patients - Impact of chemotherapy on muscle composition of breast cancer patients
Maxima Medisch Centrum0 个研究点目标入组 13 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Female breast cancer patients
- •- Age between 30-65 years
- •- 18-weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC)
排除标准
- •- Participation in an exercise rehabilitation program during the study
- •- Chronic diseases that influence skeletal muscle tissue characteristics, like type 2 diabetes mellitus, chronic obstructive pulmonary disease, chronic heart failure
- •- Chronic inflammatory disorders, like rheumatoid arthritis, colitis ulcerosa or Crohn*s disease.
- •- Musculoskeletal disorders that cause an inability to perform the maximal cycling and strength assessment.
研究者
相似试验
尚未招募
不适用
Impact of chemotherapy on muscle composition of breast cancer patients.Cancer cachexiaSpierverlies bij kankerNL-OMON25768Maxima Medisch Centrum, Veldhoven13
已完成
不适用
An evaluation of two eight-month regimens of chemotherapy for the treatment of newly diagnosed pulmonary tuberculosisSmear-positive pulmonary tuberculosisInfections and InfestationsRespiratory tuberculosis, bacteriologically and histologically confirmedISRCTN19832141International Union Against Tuberculosis and Lung Disease (France)1,500
已完成
不适用
A prospective study of the effect of chemotherapy on metabolic and cardiovascular function in women with early stage breast cancerEarly stage breast cancerCancer - BreastACTRN12614001055695A/Prof Bogda Koczwara29
进行中（未招募）
不适用
Observational study in Breast cancer patient who are taking Anthracyclin Chemotherapy to observe chemotherapy induced nausea and vomitingCTRI/2016/01/006555Tata Memorial Centre
已完成
1 期
Phase I/II study of weekly chemotherapy consisting of 5-FU, leucovorin, and Paclitaxel (FLTAX) in patients with metastatic or recurrent gastric cancer.Patients with metastatic or recurrent gastric cancerJPRN-UMIN000000502ational Cancer Center Hospital, Gastrointestinal Oncology Division35